Brain molecular imaging in pharmacoresistant focal epilepsy: Current practice and perspectives
A. Verger, S. Lagarde, L. Maillard, F. Bartolomei, Eric Guedj

To cite this version:

HAL Id: hal-02479834
https://hal.archives-ouvertes.fr/hal-02479834
Submitted on 21 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Brain molecular imaging in pharmaco-resistant focal epilepsy: current practice and perspectives

Verger A. MD, PhD\textsuperscript{1,2}; Lagarde S. MD, PhD\textsuperscript{3}; Maillard L. MD, PhD\textsuperscript{4}; Bartolomei F. MD, PhD\textsuperscript{3,5}; Guedj E. MD, PhD\textsuperscript{6,7,8}.

\textsuperscript{1} Department of Nuclear Medicine & Nancyclotep Imaging platform, CHRU Nancy, Lorraine University, France

\textsuperscript{2} IADI, INSERM, UMR 947, Lorraine University, Nancy, France

\textsuperscript{3} APHM, Timone Hospital, Clinical Neurophysiology, Marseille, France

\textsuperscript{4} Neurology Department, Nancy, France

\textsuperscript{5} Aix Marseille Univ, Inserm, INS, Institut de Neurosciences des Systèmes, UMR-S 1106, Marseille, France

\textsuperscript{6} APHM, Timone Hospital, Department of Nuclear Medicine, France

\textsuperscript{7} Aix Marseille Univ, CNRS, INT, Institut des Neurosciences de la Timone, UMR 7289, Marseille, France

\textsuperscript{8} Aix-Marseille Univ, CERIMED, Marseille, France

General Review

Words count: 4214

Address for correspondence:
Eric Guedj, M.D., Ph.D.
eric.guedj@ap-hm.fr
Service Central de Biophysique et Médecine Nucléaire, Hôpital de la Timone, 264 rue Saint Pierre, 13005 Marseille, France.
Tel: +33-491385558; Fax: +33-491384769
Abstract

This review aims at synthetizing data available in brain molecular imaging, i.e. Single Photon Emission Computer Tomography (SPECT) but also inter-ictal Fluoro-Deoxy-Glucose Positron Emission Tomography (FDG PET) in focal epilepsies. SPECT imaging is able to measure regional cerebral blood flow and its major originality remains its ictal imaging value. On the other hand, FDG PET, which has higher spatial resolution and lower background activity than SPECT, enables to define glycolytic metabolism in inter-ictal state. Therefore, inter-ictal FDG PET has higher sensitivity than inter-ictal SPECT, especially in temporal lobe epilepsies (TLE). $^{18}$F-FDG PET is thus a necessary step in pre-surgical evaluation in TLE but also in extra-temporal epilepsies (ETE) leading to contribute to more than 30% in decision of surgery. In addition, FDG PET provides a particular diagnostic value in focal epilepsy with normal MRI. Moreover, PET has a good prognostic value on post-surgical outcome as well as cognitive impairment, especially in case with limited hypometabolism extent. The notion of epileptic network is also well underlined by functional imaging, allowing to better understand substrates of this pathology. Future development of quantitative analysis software, novel radiotracers and cameras will certainly enhance its clinical utility.

Key-words: Brain molecular imaging; SPECT; FDG-PET; pharmaco-resistant focal epilepsy.
Introduction

Seventy million people in the world suffer from epilepsy, with 34 to 76 new cases diagnosed per 100,000 every year (1). Focal epilepsies are the most common forms and they are characterized by seizure onset localized in a region (the epileptogenic zone, EZ) of the cerebral cortex. Focal seizures are generally characterized by the emergence of rapid discharges occurring within networks either discretely localized or more widely distributed (2,3). Overall, more than 30% of patients with epilepsy are thought to have drug-resistant seizures (1). In this context, surgical resection of the EZ is a valid option if the potential benefit is assessed to outweigh the risk (4). This EZ corresponds to the brain area necessary and sufficient for the generation of habitual seizures, generally less extensive than the whole irritative zone (area generating the inter-ictal spikes) (5). A medico-economic analysis shows, that in addition to being safe and effective, surgery of epilepsy is cost-effective in the medium term, and should therefore be considered earlier in the treatment of refractory epilepsies (6).

Pre-operative evaluation aims to precisely define EZ. In this line, surgical techniques have been refined over years with the help of non-invasive techniques such as High-Resolution electroencephalography (EEG) and Magnetoencephalography (7,8), magnetic resonance imaging (MRI), as well as invasive techniques such as Stereotactic electroencephalography (SEEG; a stereotactic guiding for the placement of depth electrodes for intracerebral EEG monitoring). This evaluation also includes brain molecular imaging with perfusion SPECT (single photon emission computed tomography), and/or metabolic PET (positron emission tomography) using $^{18}$F-FDG ($^{18}$F-Fluorodeoxyglucose). This global approach has led to more precise localization of EZ, allowing the removal of the minimal necessary amount of tissue with reduction of post-operative neurological deficit (9). It is noteworthy that surgical final decision is taken after interpretation of all these data within multidisciplinary staff discussion.
In this context, this review aims at synthetizing data available in brain molecular imaging, i.e. SPECT but also inter-ictal FDG PET in focal pharmaco-resistant epilepsies (temporal (TLE) and extra-temporal (ETE)). Future perspectives would also be discussed for $^{18}$F-FDG PET analysis and novel PET radiopharmaceuticals.
1. SPECT in focal epilepsy

SPECT imaging is able to measure regional cerebral blood flow (rCBF) associated with epileptic seizures (10). In this indication, its major originality remains its ictal imaging value. Actually, the radiopharmaceutical administration can be performed during an epileptic discharge, with a brain uptake irreversibly completed in one to two minutes (11). During an “ictal” scan, the brain regions involved in seizure generation and early propagation demonstrates increased perfusion, while most epileptic networks are hypoperfused during inter-ictal state (12). $^{99m}$Technetium radiolabeled tracers such as HMPAo (HexaMethylPropyleneAmine oxime) or ECD (Ethyl Cystine Dimer) are currently used. SPECT image acquisition can start 30 to 90 minutes after injection with acquisition duration of about 20 minutes, and a radiation dosimetry of approximately 6 mSv (13).

Ictal SPECT has shown a sensitivity of 73% and specificity of 75%, while inter-ictal SPECT has a much lower localization value with 50% of sensitivity and 75% of specificity (14). Moreover, SPECT has higher performances in detection of epileptic networks in temporal epilepsies in comparison to non-temporal epilepsies, in ictal as well as in inter-ictal state (15). Subtraction of ictal and inter-ictal SPECT, co-registered to MRI (SISCOM), is particularly useful (Figure 1); this has been shown to improve the sensitivity and specificity of seizure localization networks only demonstrating hypoperfusion during inter-ictal scan (16). In this line, studies found that SISCOM localization sensitivity was higher than 90% in temporal lobe seizures, but much lower in extra-temporal lobe epilepsies (17,18). Similarly, SISCOM provides useful information for seizure localization in patients with focal cortical dysplasia, even with normal MRI (19). Notably, ictal SPECT seems also suitable in children with focal refractory epilepsies associated with focal cortical dysplasia (20).
Several studies have assessed the practical clinical value of SISCOM in preoperative evaluation, comparing SISCOM with either MRI, PET, ictal EEG or EEG-fMRI, surgical site or combined modalities (21–24). For instance, hyperperfusions from SISCOM images were localized more often than with side-by-side SPECT evaluation (71.0 vs. 47.4%) (21), whereas SISCOM images led to a concordant or only slightly worth results than PET, MRI and EEG modalities alone or combined (22–24). Interestingly, if SISCOM localization is concordant with the surgical resection site or other traditional techniques, then postoperative outcomes are expected to be favorable (25–28).

Nevertheless, spatial resolution of SPECT is poor. Consequently, inter-ictal studies in focal epilepsies are currently performed with PET imaging which leads to a better sensitivity in detection of epileptic networks (29). This statement could be revised in future with instrumentation development, particularly Cadmium-Zinc-Telluride (CZT) cameras. They provide semi-conductors detectors with better sensitivity of detection, spatial and energy resolution (30).

2. \(^{18}\text{F-FDG PET in focal epilepsy}\)

PET has higher spatial resolution and lower background activity than SPECT (31). Therefore, inter-ictal PET has higher sensitivity than inter-ictal SPECT, as described in a previous meta-analysis by Spencer, especially in temporal lobe epilepsies (84 vs. 66 %) (29). One complementary explanation for this better sensitivity could also be the uncoupling of blood perfusion and metabolism, leading to more reduction in regional cerebral glucose metabolic rates than in regional cerebral perfusion. It could also be related to a shorter reversibility in perfusion state during inter-ictal phase (32). Evidence for this uncoupling was demonstrated
in prior studies using $^{15}$O-H$_2$O and $^{18}$F-FDG PET (33,34), and using ratio imaging of inter-ictal $^{99m}$Tc HMPAO SPECT divided by $^{18}$F-FDG PET (32,35).

However, even if some studies have explored ictal $^{18}$F-FDG-PET (36), the temporal resolution of $^{18}$F-FDG-PET remains weak, with a longer uptake period (30 minutes), leading to a mixture of inter-ictal-, ictal-, and postictal-phase images (31), which rends difficult the analyze of ictal $^{18}$F-FDG-PET. Some studies have nevertheless correlated interical PET hypometabolism with clinical epileptic semiology such as déjà-vu in TLE or hyperkinetic seizures in ETE (37,38).

$^{18}$F-FDG PET, which evaluates the cerebral metabolic rate for glucose (CMRGlc), visually demonstrates the whole irritative zone (i.e. the EZ and subsequent neural networks involved in the generation of inter-ictal paroxysms) (39). The fact that $^{18}$F-FDG PET sensitivity differs according to the site of the epileptogenic area is nevertheless a strong argument against a causal relationship between hypometabolism and epileptogenicity (40). Inter-ictal hypometabolism topography may be indeed related to the neuronal networks involved by ictal discharge onset and also spread pathways (41). But the origin of this hypometabolism is certainly multifactorial and several mechanisms have been hypothesized: neuronal loss in the functional deficit zone, hypometabolic macro- or microscopic lesions, decreased synaptic activity (diaschisis), deafferentation with reduced numbers of synapses, post-ictal metabolic depression (40), presence of a lesion, even if controversial by atrophy and focal volume effect (42,43), and breakdown of the inhibitory mechanisms at an advanced stage of the disease process (44). In this line, a dysfunction of neurotransmitter gamma-aminobutyric acid type A (GABA$_A$) receptor has been established in human focal epilepsy (45). This dysfunction was modulated by glycolysis, explaining the hypometabolism induced by a decrease of inhibitory mechanisms, leading to facilitate epileptic discharges. Lastly, this hypometabolism is also influenced by the delay from the last seizure, frequency of the ictal discharge, duration of the
seizure, and antiepileptic therapeutics (46). Actually, clinicians have to take into account these factors during the analysis of inter-ictal $^{18}$F-FDG PET.

Besides these PET findings, extension of hypometabolism to regions beyond the temporal lobe is often seen in patients with TLE (47,48), suggesting that hypometabolism on PET scan shows a dysfunctional neural network wider than only the EZ (49). In this context, Chassoux et al. observed in 114 patients with TLE and hippocampal sclerosis, that regardless of the structural alterations, the topography of hypometabolism correlated strongly with the extent of epileptic networks when compared to electro-clinical data (50). Otherwise, authors found remotely hypermetabolism, predominant in non-epileptic lobe and extra-temporal areas, suggesting compensatory mechanisms to cognition impairment (51–55).

Briefly, $^{18}$F-FDG PET imaging is performed after a 10 to 15 minutes resting state. Then, $^{18}$F-FDG is injected and acquisitions, during about 15 minutes, start 30 to 60 minutes after injection, with a radiation dosimetry of approximately 2.9 mSv (56).

Similarly to SPECT imaging and consequently to technological innovations, PET imaging will further improve their characteristics with the introduction of digital PET which provides better image quality, diagnostic confidence, and accuracy than analog PET. They support a spatial resolution of 4 mm and a lesion maximum SUV (Standard Uptake Value) 36% higher and lesion-to-blood-pool SUV ratio 59% higher than with conventional PET (57).

We will now discuss $^{18}$F-FDG PET indications in temporal and extra-temporal epilepsies, its relation with electroencephalography and MRI findings as well as its prognosis value.

2.1 $^{18}$F-FDG PET in Temporal Lobe Epilepsies (TLE)
Temporal lobe epilepsies (TLE) are the most common form of focal epilepsies. $^{18}$F-FDG PET has a high sensitivity for TLE with a detection range from 86 to 90% (58–61). For instance, in a 25 TLE patients study, Knowlton et al. showed that $^{18}$F-FDG PET was the most EEG correlated parameter with a sensitivity of detection of 87% (59), when compared to MRI (hippocampal volumetry, T2 relaxometry, and proton magnetic resonance spectroscopic imaging). However, so called TLE does not appear to be homogeneous from an electro-clinical point of view (5,62). They can be divided into 4 distinct subgroups: mesial (mTLE), lateral, temporal “plus” and bitemporal TLE (41). For instance, mTLE, the most frequent form of TLE (63), has proven to be one of the most medically refractory localization related to epilepsy syndromes (64). Then, in a study of 50 TLE patients, Chassoux et al. defined 4 groups of electro-clinical patterns, accordingly to distinct patterns of TLE previously mentioned, and showed a good accordance with inter-ictal $^{18}$F-FDG PET hypometabolisms at group-level (39). Moreover, in this study, the strictly mesial temporal hypometabolism had the most favorable outcome. Several studies have performed simultaneous $^{18}$F-FDG PET acquisitions and EEG recordings but the benefit remains nevertheless controversial (65,66). Although, it has been suggested that, besides its invasiveness and its limited sampling, SEEG correlates better with $^{18}$F-FDG PET findings than EEG (65), leading to direct comparison between $^{18}$F-FDG PET findings and SEEG (67). In this context, authors found correspondence between SEEG findings and metabolic PET characterization at the group level; they validated also the results at individual level with a high accuracy of 71.4% to 88.2% (41). As expected, the hypometabolism was not limited to the EZ defined by SEEG, underlying larger epileptic networks (41). More recently, authors have directly compared ictal high frequencies oscillations (HFO) recorded by SEEG with hypometabolism in inter-ictal $^{18}$F-FDG PET, and showed that temporal hypometabolic regions are more likely to present high frequencies oscillations (68). Consequently, the authors suggested that inter-ictal FDG-
PET hypometabolism and ictal high frequencies oscillations (HFO) may share common pathophysiologic mechanisms (68).

Because of the different electro-clinical presentations of the TLE, \(^{18}\text{F-FDG}\) PET appears as a very useful tool in these epilepsies. In a study of 117 patients with drug refractory epilepsy, \(^{18}\text{F-FDG}\) PET helped in surgical decision-making in 68.8% of TLE, and was particularly efficient in case of mesial temporal sclerosis lesion (69).

\[2.2 \text{ } ^{18}\text{F-FDG PET in Extra-Temporal Lobe Epilepsies (ETE)}\]

Extra-temporal lobe epilepsies (ETE) are less frequent than TLE, and frontal lobe epilepsies (FLE) constitute the most common form of ETE (63). Visual assessment of \(^{18}\text{F-FDG}\) PET rates from 38 to 67% according to ETE studies (60,70,71) and, similarly to TLE, hypometabolism in \(^{18}\text{F-FDG}\) PET is worse in patients with structural lesions than in patients without one (70). In this line, it is noteworthy that \(^{18}\text{F-FDG}\) PET is of particular interest in the patients with epilepsies associated with focal cortical dysplasia, even in children (72–77). This hold true for a wide spectrum of malformations of cortical development including polymicrogyria whose the heterogenous epileptogenicity correlates well with the heterogenous pattern of hypo and isometabolism (78,79). In addition, as reported in a study of 117 patients, ETE exhibited less great concordance with electro-clinical data (28.6%) in comparison to TLE (78.0%) (69). Nevertheless, in a study involving 13 children, Silva et al. showed a sensitivity and specificity of \(^{18}\text{F-FDG}\) PET of 92% and 62.5% respectively (80). This high sensitivity detection was mostly due to the fact that children with FLE also frequently exhibited glucose metabolic abnormalities outside the frontal lobes. In a study of 194 patients with refractory epilepsy, involving 66 FLE and 38 others ETE, Rathore et al. showed that the proportion of abnormal \(^{18}\text{F-FDG}\) PET was of 52% in FLE and 61% in other
ETE, lower than in TLE (67 %). Moreover, concerning the usefulness of PET in further decision making, $^{18}$F-FDG PET data were useful in respective 38 % of FLE, 50 % of other ETE and 63 % of TLE (81). The authors argued that certain ETE locations such as the mesio-frontal, occipital and operculo-insular regions are difficult to detect with $^{18}$F-FDG PET. This relative weak sensitivity of ETE detection has led to the use of quantitative analysis in order to improve diagnosis confidence (82,60), although it remains debated (70).

If ETE detection appears less sensitive than TLE with $^{18}$F-FDG PET, pathophysiology of these epilepsies are also complex with extensive network involved, including mesial temporal areas (82,71). In this line, 22% of patients with ETE exhibited temporal hypometabolism in a study by Hartl and al (83), mostly associated with temporal inter-ictal epileptic discharges (64% of temporal hypometabolism). Interpretation of inter-ictal FDG-PET results requires thus consideration of EEG results and seizure semiology since common temporal glucose hypometabolism in ETE patients may reflect a remote epileptic dysfunction arising from extra-temporal epileptogenic zones.

3. $^{18}$F-FDG PET and MRI

In a significant number of cases, MRI do not reveal any epileptogenic lesion (84), even using 7 tesla MRI (85), although about 26% of patients with refractory focal epilepsies remains “MRI-negative” (86). In this context of normal MRI, authors showed nevertheless a focal or lateralized regional hypometabolism in PET, concordant to the ictal electroclinical data in 27 patients with various types of intractable epilepsies (41.5%) (69). Similarly, in cases of drug resistant TLE with normal MRI, the surgical outcome has been found to be better in case of temporal hypometabolism. An example of multimodality pre-operative assessment of a TLE in a patient with normal MRI is given in Figure 3.
Several studies have specifically analyzed post-surgery outcome of these patients with PET positive and normal MRI. They observed that patients with positive PET had similar rates of good outcome (Engel I = seizure-free) regardless of the presence or absence of a MRI detectable lesion (67,87) and close to the surgical prognosis of patients with hippocampal sclerosis (88). In this line, patients with positive PET, even if associated to MRI negative data, should be considered as potential candidates to surgery. Moreover, the MRI is often reviewed in the light of PET findings, with the opportunity to co-register the two complementary imaging modalities, as currently recommended in the pre-surgical evaluation of intractable epilepsy (89,90). An example is provided in Figure 2. These two modalities are indeed complementary rather than redundant since hypometabolism in $^{18}$F-FDG PET was not related with severity of hippocampal sclerosis nor temporal atrophy defined on MRI (39,43,91,92).

The interest of FDG-PET/MRI coregistration was also highlighted in patients with focal cortical dysplasia, especially in younger patients with temporal localization who exhibit larger hypometabolism on $^{18}$F-FDG-PET (73,93). In a study of 23 patients operated for intractable focal epilepsy associated with focal cortical dysplasia and normal MRI, the use $^{18}$F-FDG PET led to the detection of the lesion in 95% of the patients (75). Then, $^{18}$F-FDG PET exhibited not only hypometabolism in 78% cases, but also led to the detection of 4 additional cases when using co-registration with MRI, which is efficient and routinely available. More recently, an initial hybrid PET-MRI experience has increased diagnostic yields for detection of EZ (94). Authors suggested that it could be due to the unique advantage of improved co-registration, and simultaneous review of both structural and molecular data.

4. $^{18}$F-FDG PET and clinical outcome
18F-FDG PET is a part of the systematic pre-surgical assessment of drug-resistant epilepsies. A study based in surgical-decision-making has shown that 31.6% patients were directly selected for surgery based on PET contribution (69). 18F-FDG PET was more helpful in surgical decision-making in TLE (68.8% of cases), than in ETE (23.3% of cases) (69). As previously discussed, clinical outcome of patients with positive PET findings and MRI negative is similar to those with positive MRI data (67,87).

Moreover, the post-operative status is also influenced by PET findings. In a meta-analysis of 46 studies, authors showed that PET hypometabolism ipsilateral to the EZ in TLE had a predictive value of 86% for good outcome (Engel classes I or II after surgery) (49). However, if the usefulness of 18F-FDG PET to accurate localize epileptic networks is well-established leading to good outcome (95), the prognostic value of hypometabolism extent remains debated. In a 30 TLE patients study, Dupont et al. observed a better clinical outcome after surgery if the hypometabolism extent was limited (96). Similarly, patients with TLE and normal MRI, those with a good outcome had a greater proportion of total hypometabolic volume resected than those with a poor outcome (24.1% versus 11.8%) (97). On the opposite, in a study analyzing associations between PET findings and neocortical epilepsies surgery outcome, authors showed no significant correlations between the amount of non-resected 18F-FDG PET abnormalities and the surgical outcome (98). It is noteworthy that this last study included ETE, which are known to have more subsequent remote hypometabolism (83). On the whole, 18F-FDG PET has a good prognostic value on post-surgical outcome, especially in case with limited hypometabolism extent (96,97).

Besides its prognostic value on post-surgical outcome, 18F-FDG PET also allows to explore cerebral networks involved in epilepsy and their link with the cognitive alterations in TLE. First studies with 18F-FDG PET have shown an association between decrease of metabolic
value and cognition impairment in TLE (99,100). Then, correlations have been shown between cognitive impairment and metabolic values of hippocampal or para-hippocampal areas (101,102). Otherwise, studies focusing on extra-temporal hypometabolism in TLE have also been conducted, showing association between: left temporal pole hypometabolism and memory of famous faces (103), left temporo-occipital areas hypometabolism and deficit on word findings (104), or prefrontal areas hypometabolism and impairment of executive functions (105). In a study of 15 TLE patients with hippocampal sclerosis, authors have observed correlations between number of correctly recognized targets in a new recognition memory paradigm and inter-ictal entorhinal/perirhinal cortices metabolic rate for glucose (55).

In ETE, a $^{18}$F-FDG PET study in 9 patients with occipital lobe epilepsy has revealed verbal memory impairment selectively associated with left temporal lobe hypometabolism, supporting a link between neuropsychological dysfunction and remote hypometabolism in focal epilepsies (106). Therefore, in addition to prognostic value on seizure control outcome, $^{18}$F-FDG PET provides a prognostic value on cognition: a limited hypometabolism, particularly in limbic areas, being a better prognostic factor for post-operative cognitive functioning (101,102,55).

5. Analysis of $^{18}$F-FDG PET imaging

Visual assessment remains the gold standard for detection of hypometabolism in epilepsy, regards to expert interpretation and discussion with clinicians based on other available data. SPECT SISCOM (16) and co-registration between PET and MRI (89,90) have already been discussed previously, and could be particularly contributive. In some cases, quantitative analysis could also be helpful (107–110), especially for extra-temporal epilepsies (60,70).
Some studies analyzed inter-hemispheric asymmetries, such as left to right subtraction, or the asymmetry index, and showed improvement of preoperative evaluations for TLE. In most such studies, inter-hemispheric asymmetry was calculated from the mean region-of-interest value or the volume-of-interest (111,112) whereas other studies have applied asymmetries to voxel-based analysis (113). Voxel-based quantitative analysis is a valuable tool to detect subsequent epileptic networks by voxel-to-voxel comparison of two PET image dataset (60). An example of quantitative analysis is available in Figure 4. In a study of 41 patients with epilepsy, Van’t Klooster et al. showed that, although sensitivity of detection was similar between visual assessment and quantitative analysis, this last procedure detected 4 on 5 initially visual defined negative scans (108). The authors concluded that quantitative analysis could be an efficient complementary tool to visual assessment. The choice of quantitative analysis software does not appear to really influence results while an original algorithm of spatial normalization (107) or a fully-automated software of quantitative analysis (110) exhibited similar results to the well-validated software Statistical Parametric Mapping (114).

Some authors have proposed thresholds with liberal p-values and restrictive cluster sizes in order to maximize accuracy of these quantitative analyses (109).

In addition to particularly useful co-registration to MRI previously described above (89,90), taking into account focal volume effect, induced by lower spatial resolution in PET, is also efficient. In this line, Goffin et al. showed that using reconstruction algorithm with inclusion of focal volume effect improved visual detection of epileptic networks on brain $^{18}$F-FDG PET images, in particular setting of focal cortical dysplasia, due to higher contrast and better delineation of the lesion (115).

6. Novel PET imaging radiotracers for epilepsy
In addition to $^{18}$F-FDG PET imaging, novel PET radiotracers have been developed in epilepsy, especially in research. They need for this purpose a radiochemistry platform next-to the PET imaging center.

$^{11}$C-flumazenil (FMZ) PET studies targeting GABA$_A$-central benzodiazepine receptor complex (GABAAcBZ) have demonstrated reduced binding of tracer in the epileptic networks of patients (116,117). $^{11}$C-FMZ PET failed nevertheless to detect epileptic networks in 20% of patients with refractory TLE and normal high-quality MRI in a study performed by Koepp et al. (118), and its reproducibility is debated especially when using pons as a reference tissue (119).

Several studies have been conducted with 2'-methoxyphenyl-(N-2'-pyridinyl)-p-fluorobenzamidoethyipiperazine ($^{18}$F-MPPF) which is an antagonist of 5-HT1A receptors (120,121). 5-HT1A receptors are decreased in patients with epilepsy compared with normal subjects leading to a decrease of $^{18}$F-MPPF uptake in epileptic networks. Therefore, this decrease is highly correlated to the degree of epileptogenicity of cortical areas explored by intracerebral EEG recordings and does not reflect only pathological changes or neuronal loss in the epileptic focus, by underlining epileptic network (120,121).

Otherwise, by using a non-selective opioid receptor antagonist, $^{11}$C-diprenorphine (DPN), authors have experimented a post-ictal increase in $^{11}$C-DPN in the parahippocampal gyrus ipsilateral to the epileptic focus. Thus, this study provides further direct human in vivo evidence for changes in opioid receptor availability in TLE following seizures (122).

Moreover, metabotropic glutamate receptor type 5 (mGluR5) abnormalities have been described in tissue resected from epilepsy patients with focal cortical dysplasia. In a recent study, $^{11}$C-ABP688, a radiotracer of mGluR5, showed in vivo evidence of reduced mGluR5
availability in focal cortical dysplasia, indicating focal glutamatergic alterations in malformations of cortical development (123).

Neuro-inflammation has also been studied in epilepsy. In this context, $^{11}$C-PBR28 and $^{11}$C-DPA-713, radiotracers of Translocator protein 18 kDa (TSPO), had increased uptake in both areas ipsilateral and contralateral to seizure networks in patients with TLE, suggesting an inflammatory effect in this epilepsies (124).

Others studies involving N-methyl-d-aspartate (NMDA) receptors, which are ligand-gated and voltage-gated ion channels that mediate fast excitatory neurotransmission in the central nervous system, have been performed. In this line, increased NMDA channel activation was detected in patients with focal epilepsy by using $^{18}$F-GE-179, a ligand that selectively binds to the open NMDA receptor ion channel (125).

Among all these novel radiotracers, $^{11}$C-alpha-methyl-L-tryptophan (AMT) is the most studied and validated (126–128). $^{11}$C-AMT is a radiolabeled tryptophan analogue to study synthesis of serotonin in the brain. Inter-ictal PET studies have demonstrated a focal increased uptake of this radiotracer in epileptogenic areas (126–128). Focal increase of cortical $^{11}$C-AMT uptake is nevertheless less sensitive but more specific for the lobe of seizure onset than corresponding $^{18}$F-FDG PET hypometabolism (128). It is also often associated with epileptogenic cortical developmental malformations (128). Thus $^{11}$C-AMT can assist placement of intracranial electrodes even when MRI and FDG-PET fail to provide adequate localizing information.

However, despite their many advantages, majority of non-FDG brain PET studies are not widely available and performed in limited centers only as they require well experienced staff with on-site radiochemistry equipment and cyclotron. Moreover, novel tracers using
neurotransmitter are highly influenced by medications interactions, especially in patients with anti-epileptic therapies (129).

Conclusion

To conclude, brain molecular imaging and especially $^{18}$F-FDG PET imaging, is a valuable tool for epilepsy imaging, widely studied and validated. $^{18}$F-FDG PET is thus a necessary step in pre-surgical evaluation in TLE but also in ETE leading to contribute to more than 30% in decision of surgery. Its association with others pre-surgical data such as MRI or electro-clinical data improves its accuracy during the multi-disciplinary staff discussion. Moreover, $^{18}$F-FDG PET imaging provides an interesting prognostic value in clinical outcome and with potential cognitive impairment association. The notion of epileptic network is also well underlined by this functional imaging, allowing to better understand substrates of this pathology. Future development of quantitative analysis software, novel radiotracers and cameras will certainly enhance its clinical utility.

Conflict of interest: None

Acknowledgements:

This work has been carried out thanks to the support of the A*MIDEX project (n° ANR-11-IDEX-0001-02) funded by the « Investissements d’Avenir » French Government program, managed by the French National Research Agency (ANR), and thanks to Cyclopharma grant.
This work has been carried out within the FHU EPINEXT with the support of the A*MIDEX project (ANR-11-IDEX-0001-02) funded by the "Investissements d'Avenir" French Governement program managed by the French National Research Agency (ANR).

References


**Figure Legends**

**Figure 1.**

Axial slices of perfusion SPECT imaging in ictal phase (A), inter-ictal phase (B) and after subtraction of ictal and inter-ictal SPECT images co-registered to MRI (SISCOM, C) in a 40 years-old man with right temporal epilepsy. A hyperperfusion is noticed in right mesial temporal area (white arrow in A), which is hypoperfused in inter-ictal state (white arrow in B). The subtraction of ictal and inter-ictal states reveals a significant differential in perfusion in this same area, which corresponds to right mesial temporal lobe when co-registered to MRI (white arrow in C).

**Figure 2.**

Axial slices of T1-weighted-sequence MRI (A), $^{18}$F-FDG PET imaging (B) and co-registration of MRI and PET imaging (C) in a 35 years-old woman with right temporo-insular epilepsy. MRI was interpreted as negative (A). $^{18}$F-FDG PET shows a hypometabolism in right insulo-opercular area (white arrow in B and C).

**Figure 3.**

Multimodality pre-operative assessment in a patient of 39 years-old with pharmaco-resistant seizures. The seizures were characterized by dreamy state ("déjà-vu"), visual complex hallucination (object size modification), eyes staring, consciousness alteration and oral automatisms. The cerebral MRI was normal. The patient was operated of right temporal
lobectomy from the temporal pole until posterior hippocampus. The histology revealed a focal cortical dysplasia. The patient improved significantly after surgery (Engel Classe II after 2 years of follow-up). Axial slices of SPECT imaging (A) showed a hypoperfusion in inter-ictal state (upper panel, white arrow), a hyperperfusion in ictal state (middle panel, white arrow) and a significant differential of perfusion after subtraction of ictal and inter-ictal state (lower panel, white arrow in A and 3D render volume in B) of the right temporal pole. PET imaging (C) showed a hypometabolism in the right temporal lobe in axial slice (upper panel, white arrow) and in coronal slice (lower panel, white arrow). The SEEG ictal recording (D) showed an EZ including (most rapid discharges): right temporal pole (TP 1-2-3), temporo-basal cortex (TB 2-3-4), amygdala (A1-2-3), anterior (B1-2-3) and posterior (C1-2-3) hippocampus and middle temporal gyrus (A13-14). In this patient was also implanted electrodes recording: lateral temporal cortex (TP9-10, TB9-10-11, A13-14, B11-12-13, C13-14, H14-15), frontal opercula (OF8-9), occipito-temporal junction (OT1-2, OT9-10) and anterior insula (OF1-2).

**Figure 4.**

Anatomical localization with quantitative analysis, using SPM 8 software in a 31 years-old man with right temporal epilepsy, after comparison to PET images of a normal local database (n=18). Results are projected onto 3D volume rendering (A) and sections of a normal MRI centered on right mesial temporal area (B) and set spatially normalized and smoothed into the standard SPM8 template after using an inclusive right mesial temporal mask. A hypometabolism is noticed in right mesial temporal lobe (p<0.05, with correction for multiple comparisons).
Figure 1
Figure 2
Figure 4